The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 19, 2020
Filed:
Mar. 15, 2013
Applicant:
S.l.a. Pharma Ag, Liestal, CH;
Inventors:
David Nigel Armstrong, Lawrenceveille, GA (US);
Justin Slagel, Watford, GB;
Assignee:
S.L.A. PHARMA, AG, Liestal, CH;
Primary Examiner:
Int. Cl.
CPC ...
A01N 45/00 (2006.01); A61K 31/56 (2006.01); A61K 31/4164 (2006.01); A61K 9/00 (2006.01); A61K 31/192 (2006.01); A61K 31/24 (2006.01); A61K 31/245 (2006.01); A61K 31/355 (2006.01); A61K 31/407 (2006.01); A61K 31/4166 (2006.01); A61K 31/545 (2006.01); A61K 31/573 (2006.01); A61K 31/60 (2006.01); A61K 31/65 (2006.01); A61K 33/30 (2006.01); A61K 45/06 (2006.01); A61K 9/06 (2006.01); A61K 47/06 (2006.01); A61K 47/44 (2017.01);
U.S. Cl.
CPC ...
A61K 31/4164 (2013.01); A61K 9/0014 (2013.01); A61K 9/0031 (2013.01); A61K 9/06 (2013.01); A61K 31/192 (2013.01); A61K 31/24 (2013.01); A61K 31/245 (2013.01); A61K 31/355 (2013.01); A61K 31/407 (2013.01); A61K 31/4166 (2013.01); A61K 31/545 (2013.01); A61K 31/573 (2013.01); A61K 31/60 (2013.01); A61K 31/65 (2013.01); A61K 33/30 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/44 (2013.01);
Abstract
A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.